Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 May 15:13:219.
doi: 10.1186/1471-2334-13-219.

Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

Piroon Mootsikapun, Po-Ren Hsueh, Deepak Talwar, Vilma M Co, Viraj Rajadhyaksha, Moh-Lim Ong
Clinical Trial

Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

Piroon Mootsikapun et al. BMC Infect Dis. .

Abstract

Background: Candidemia is a significant cause of morbidity and mortality in hospitalized patients, particularly in Asia. Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different.

Methods: An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. Treatment was initiated with intravenous anidulafungin, given for at least 5 days, with the option to complete treatment with oral voriconazole. The primary endpoint was global (clinical and microbiological) response, and the primary analysis was the proportion of patients in the modified intent-to-treat population with successful global response at the end of therapy. Secondary analyses included proportion with successful global response in clinically relevant patient subgroups. The safety and tolerability profile of anidulafungin and voriconazole in this population was also investigated.

Results: Forty-three patients were studied, including 42 in the modified intent-to-treat population. Eighteen patients were > 65 years, the largest age subgroup, and 21 had central venous catheters. The most common Candida species causing infection were C. tropicalis (n = 18) and C. albicans (n = 10). In the primary analysis, 73.8% had a successful global response at end of therapy. Success rates in subgroups were: 72.2% for C. tropicalis and 71.4% for C. albicans infection, 58.8% for patients > 65 years, and 81.0% for patients with central venous catheters. Safety and tolerability were comparable with the known profiles for anidulafungin (and voriconazole).

Conclusions: Although the epidemiology of Candida infections was different in this open-label study, the efficacy of anidulafungin in Asian patients with documented candidemia was consistent with previous studies in Western populations. No new safety concerns were identified.

Trial registration: http://www.clinicaltrials.gov identifier NCT00537329.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow chart.
See this image and copyright information in PMC

References

    1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163. doi: 10.1128/CMR.00029-06. - DOI - PMC - PubMed
    1. Hsueh PR, Graybill JR, Playford EG, Watcharananan SP, Oh MD, Ja’alam K, Huang S, Nangia V, Kurup A, Padiglione AA. Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific region. Int J Antimicrob Agents. 2009;34:205–209. doi: 10.1016/j.ijantimicag.2009.03.014. - DOI - PubMed
    1. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48:1366–1377. doi: 10.1128/JCM.02117-09. - DOI - PMC - PubMed
    1. Chang A, Neofytos D, Horn D. Candidemia in the 21st century. Future Microbiol. 2008;3:463–472. doi: 10.2217/17460913.3.4.463. - DOI - PubMed
    1. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–1703. doi: 10.1086/599039. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources